Frank, David A.

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 677

Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4

Wang, K. S., Frank, D. A., & Ritz, J. (2000) · Blood

Immune Cell Function and InteractionCytokine Signaling Pathways and Interactions

Cited by 241

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

Takakura, A., Nelson, E. A., Haque, N., Humphreys, B. D., Zandi-Nejad, K., Frank, D. A., & Zhou, J. (2011) · Human Molecular Genetics

Genetic and Kidney Cyst DiseasesTuberous Sclerosis Complex Research

Cited by 143

Development of Selective Covalent Janus Kinase 3 Inhibitors

Tan, L., Akahane, K., McNally, R., Reyskens, K. M. S. E., Ficarro, S. B., Liu, S., Herter-Sprie, G. S., Koyama, S., Pattison, M. J., Labella, K., et al. (2015) · Journal of Medicinal Chemistry

Cytokine Signaling Pathways and InteractionsHeterocyclic Compound Synthesis and Bioactivity

Cited by 122

The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer

Khan, M. W., Saadalla, A., Ewida, A. H., Al-Katranji, K., Al-Saoudi, G., Giaccone, Z. T., Gounari, F., Zhang, M., Frank, D. A., & Khazaie, K. (2018) · Cancer Immunology, Immunotherapy

Cytokine Signaling Pathways and InteractionsCancer Immunotherapy and Biomarkers

Cited by 103

Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors

Heppler, L. N., & Frank, D. A. (2017) · Trends in Cancer

Cytokine Signaling Pathways and InteractionsProtein Tyrosine Phosphatases

Cited by 74

Deletion of STAT3 from Foxd1 cell population protects mice from kidney fibrosis by inhibiting pericytes trans-differentiation and migration

Ajay, A. K., Zhao, L., Vig, S., Fujiwara, M., Thakurela, S., Jadhav, S., Cho, A., Chiu, I.-J., Ding, Y., Ramachandran, K., et al. (2022) · Cell Reports

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 47

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy

Liu, S., Marneth, A. E., Alexe, G., Walker, S. R., Gandler, H. I., Ye, D. Q., Labella, K., Mathur, R., Toniolo, P. A., Tillgren, M., et al. (2018) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 33

Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3?

Heppler, L. N., & Frank, D. A. (2019) · Cancer Cell

Protein Degradation and InhibitorsCytokine Signaling Pathways and Interactions

Cited by 23